Moderna Stock Price, News & Analysis

Moderna (NASDAQ:MRNA) has been ranked as the top large employer in BioSpace's 2025 Best Places to Work report for the fourth consecutive year. The recognition highlights the company's reputation and commitment to innovation. Moderna continues to invest in employee development through initiatives like its AI Academy and AI-powered tools. The company was also recently recognized in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna's focus remains on creating an environment fostering meaningful careers while pursuing its mission of delivering multiple products in the coming years.

Carisma Therapeutics (NASDAQ: CARM) announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed with Moderna. The therapy demonstrated ability to create CAR-M directly in vivo, reprogramming myeloid cells to target GPC3-expressing cancer cells. Pre-clinical results showed specificity for GPC3 tumor antigen with dose-dependent cytotoxicity against GPC3+ tumor cells. In both syngeneic and humanized tumor models, the therapy significantly reduced tumor burden and suppressed liver metastasis. The treatment was well-tolerated in mouse models, showing promise as an off-the-shelf treatment for GPC3+ solid tumors, including HCC.

Moderna (NASDAQ:MRNA) has received Health Canada approval for mRESVIA, an RSV vaccine for adults aged 60 and older. This marks Moderna's second approved product in Canada and the first mRNA vaccine against RSV. The vaccine, available in a unique pre-filled syringe format, is approved for preventing lower respiratory tract disease caused by RSV. The approval is based on Phase 3 ConquerRSV trial data involving 37,000 adults. Supply is expected in Canada in early 2025. The National Advisory Committee on Immunization recommends the vaccine for people aged 75+ and those 60+ in nursing homes, while community-dwelling adults 60+ can decide individually with their healthcare provider.

Moderna reported Q3 2024 financial results with revenues of $1.9 billion and GAAP net income of $13 million ($0.03 EPS). Product sales reached $1.8 billion, including $1.2 billion in U.S. sales and $0.6 billion internationally. The company reiterates 2024 expected product sales of $3.0-3.5 billion. Cost of sales decreased 77% to $514 million. R&D expenses decreased 2% to $1.1 billion, while SG&A expenses dropped 36% to $281 million. Cash position stands at $9.2 billion. The company initiated Phase 3 trials for norovirus and influenza vaccines, and expanded its Executive Committee.

Carisma Therapeutics (Nasdaq: CARM) announced new pre-clinical data presentation on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC) at SITC 2024. The therapy, developed with Moderna, uses lipid nanoparticles to deliver mRNA that reprograms endogenous myeloid cells, creating an off-the-shelf treatment approach for GPC3+ solid tumors.

The data, demonstrating robust anti-tumor activity, will be presented on November 8, 2024, at the SITC Annual Meeting in Houston, Texas. The presentation focuses on targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. Two posters will be presented, including one on the pre-clinical efficacy of anti-GPC3 CAR-M and another on a Phase 1 study of anti-HER2 CAR therapy.

Moderna (NASDAQ:MRNA) has announced its participation in three major healthcare conferences in November 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 12th at 10:00am ET, the UBS Global Healthcare Conference on November 13th at 3:30pm PT, and the Jefferies London Healthcare Conference on November 21st at 2:00pm GT. Live webcasts of all presentations will be accessible through the Investors section of Moderna's website, with replays available for at least 30 days after each event.

Merck (MRK) and Moderna have initiated INTerpath-009, a Phase 3 clinical trial evaluating V940 (mRNA-4157) combined with KEYTRUDA for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). The trial targets patients who didn't achieve complete response after neoadjuvant KEYTRUDA plus platinum-based chemotherapy. This marks the third Phase 3 trial for V940, focusing on earlier cancer stages. Patient enrollment has begun in Canada, expanding the companies' collaborative INTerpath clinical program which includes trials for melanoma, lung cancer, cutaneous squamous cell carcinoma, renal cell carcinoma, and urothelial carcinoma.

Moderna (NASDAQ:MRNA) has been named a top employer in the global biopharmaceutical industry by Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. The company was recognized for its innovation, employee respect, and social responsibility.

Key 2024 achievements include implementing ChatGPT Enterprise across the organization, establishing a new global headquarters in Cambridge, Massachusetts, and continuing development of a Marlborough manufacturing site. The company also celebrated the second anniversary of its Charitable Foundation and released its third ESG Report.

The Science survey gathered over 6,400 responses from readers worldwide, with 65% from North America, 19% from Europe, and 11% from Asia/Pacific Rim.

Moderna (NASDAQ:MRNA) has announced its plans to report third quarter 2024 financial results on Thursday, November 7, 2024. The company will host a live conference call and webcast at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors can access the live webcast through the 'Events and Presentations' section of Moderna's website. The archived webcast will be available approximately two hours after the conference call and will remain accessible for one year following the event. This announcement serves as a notice to shareholders and interested parties about the upcoming financial disclosure and opportunity to gain insights into Moderna's recent performance and future outlook.